Study identifier:D5161R00072
ClinicalTrials.gov identifier:NCT07413757
EudraCT identifier:N/A
CTIS identifier:N/A
A cross-sectional survey-based study using preference elicitation method to assess decision-making impact factor of Chinese patients and physicians for first-line EGFR-TKIs treatment of stage IV NSCLC (CHOICE)
Non-small Cell Lung Cancer
N/A
No
-
All
590
Observational
18 Years - n/a
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Feb 2026 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions |
|---|---|
| Physicians group Physicians who have experience in the treatment and management of stage IV NSCLC patients with 1L EGFR-TKI. | - |
| Patinet group Patients receiving or who have received 1L EGFR-TKI treatment for stage IV NSCLC | - |